Telomerase Loss Drives Heart Failure Through Mitochondrial Oxidative Stress
TERT-deficient progeria mice reveal how aging-related mitochondrial dysfunction triggers cardiac electrical and structural remodelling.
Summary
Researchers engineered third-generation telomerase-deficient (TERT-/-) mice to model accelerated aging and study its effects on heart function. These mice showed reduced cardiac output, increased fibrosis, and abnormal electrical conduction. RNA sequencing and biochemical assays pointed to mitochondrial oxidative stress as a central driver, with elevated markers like malondialdehyde and disrupted mitochondrial dynamics proteins MFN2 and Drp1. The findings suggest that telomerase deficiency accelerates cardiac aging through mitochondrial dysfunction, and that targeting mitochondrial quality control could offer a therapeutic avenue for age-related heart failure.
Detailed Summary
Heart failure disproportionately affects older adults, yet the molecular mechanisms connecting cellular aging to cardiac decline remain poorly understood. This study tackles that gap by examining how telomerase deficiency — a hallmark of biological aging — drives structural and electrical changes in the heart.
Researchers created third-generation homozygous TERT-/- mice, which lack telomerase reverse transcriptase and undergo accelerated aging. Compared to wild-type controls, these mice showed elevated expression of aging biomarkers including p53 in cardiac tissue, confirming their senescent phenotype.
Cardiac assessments revealed significant dysfunction across multiple dimensions. Echocardiography showed reduced left ventricular ejection fraction and fractional shortening, indicating both systolic and diastolic impairment. Histology confirmed interstitial fibrosis and inflammatory infiltration, with upregulated collagen type I and TGF-β. Electrocardiography and epicardial mapping revealed prolonged QRS duration and slowed, heterogeneous ventricular conduction — hallmarks of electrical remodelling that elevate arrhythmia risk.
RNA sequencing and biochemical analysis identified mitochondrial oxidative stress pathways as centrally upregulated. Levels of malondialdehyde (a lipid peroxidation marker) and MnSOD were elevated, while mitochondrial dynamics proteins MFN2 and Drp1 were downregulated, indicating disrupted mitochondrial fusion and fission. Ultrastructural imaging confirmed mitochondrial damage.
The study's implications are significant: it positions mitochondrial quality control as a potentially druggable target in aging-related heart failure. Caveats include reliance on a mouse model with accelerated rather than natural aging, and the absence of pharmacological intervention data to validate therapeutic hypotheses directly.
Key Findings
- TERT-/- progeria mice showed reduced ejection fraction and fractional shortening, confirming both systolic and diastolic dysfunction.
- Increased interstitial fibrosis and TGF-β and collagen type I expression indicate structural cardiac remodelling with aging.
- Prolonged QRS duration and slowed conduction velocity point to significant electrical remodelling and arrhythmia risk.
- Mitochondrial oxidative stress markers (malondialdehyde, MnSOD) were elevated alongside downregulation of MFN2 and Drp1.
- RNA sequencing identified mitochondrial dysfunction pathways as central drivers of aging-related cardiac decline.
Methodology
Third-generation homozygous TERT-/- mice were used as an accelerated aging model. Cardiac function was assessed via echocardiography and electrocardiography with epicardial mapping; tissue was analyzed by histology, RNA sequencing, and biochemical assays for oxidative stress markers and mitochondrial ultrastructure.
Study Limitations
The TERT-/- model represents accelerated rather than physiological aging, limiting direct translation to human age-related heart failure. The study is descriptive and mechanistic; no pharmacological interventions targeting mitochondrial pathways were tested to confirm causality or therapeutic potential.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: